Encora Therapeutics is excited to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. The study assessed the safety, tolerability, and effectiveness of Encora’s innovative wrist-worn stimulation device for individuals with essential tremor…
Vir Biotechnology, Inc. (NASDAQ:VIR) today revealed positive results from the SOLSTICE Phase 2 clinical trial evaluating its investigational combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). The trial, which included both monotherapy and combination therapy…
HistoSonics, the developer of the Edison® Histotripsy System, has announced the enrollment of the first patients in its novel BOOMBOX study, a prospective master protocol designed to assess the real-world application of histotripsy for treating liver tumors. This post-market study…
Lobe Sciences, Ltd. (CSE: LOBE, OTCQB: LOBEF) and Alera Pharma, Inc. today announced the receipt of a second patent allowance for their Conjugated Psilocin™ technology. The patent, titled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof,” covers compositions that…
SOLVD Health, a patient intelligence company focused on precision solutions to improve health outcomes, has launched a comprehensive post-approval study for AvertD®, the first FDA-approved genetic test to assess the risk of opioid use disorder (OUD). The study will build…
Alafia AI, Inc. (“ALAFIA”), a leader in omics computing and precision medicine, is today unveiling an expansion of its high-performance computing (HPC) product line to address the growing demand for scalable, heterogeneous computing in the biopharmaceutical and application development industries.…
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) commended the American College of Rheumatology (ACR) for its newly released 2024 evidence-based guidelines on the screening, treatment, and management of lupus nephritis (LN). The updated guidelines emphasize the urgent need for effective treatments to…
RheaVita, a leader in controlled, continuous freeze-drying technology for biopharmaceuticals, has entered into a strategic partnership with IMA Life, a global leader in advanced aseptic pharmaceutical production solutions and one of the three pharma divisions of IMA Group. The partnership…
At the ISPOR Europe 2024 Conference, CapeStart, Inc. unveiled MadeAi™, a generative AI-powered platform designed to revolutionize the synthesis of clinical information. The platform’s first solution, MadeAi-LR, enhances the efficiency of systematic literature reviews (SLRs), clinical evidence reports (CERs), meta-research,…
BrightHeart, an innovator in AI technology for obstetrics and pediatric cardiology, has received FDA 510(k) clearance for its first AI-driven software, which aims to revolutionize prenatal ultrasound evaluations of the fetal heart. This breakthrough comes at a critical time, as…
